Atrial Fibrillation
Atrial fibrillation (AF) is a heart condition characterized by an irregular and often rapid heartbeat, which can lead to poor blood flow and increase the risk of stroke.
Atrial Fibrillation: AP31969 Medication Study
We are testing a new medication, AP31969, for people with atrial fibrillation to see if it helps control their heart rhythm and improve their quality of life. The study will also evaluate the safety of this treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have a diagnosis of atrial fibrillation (AF)?
- Are you currently pregnant or breastfeeding?
- Are you taking any antiarrhythmic medications like Flecainide or Sotalol?
- Do you have uncontrolled high blood pressure?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ap31969
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
Department of Invasive Cardiology
Plovdiv, Bulgaria
Acibadem City Clinic Diagnostic And Consultation Center Ltd.
Cardiology Department
Sofia, Bulgaria
Alexandrovska University Hospital
Clinic of Cardiology
Sofia, Bulgaria
Sponsor: Acesion Pharma ApS
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.